LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

Home・Aandelen Lijst・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Open

28.53 -1.35

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.42

Max

29.38

Belangrijke statistieken
By Trading Economics
Inkomsten	-30M -30M
Verkoop	-26M 77M
Winstmarge	-38.823
Werknemers	524
EBITDA	-12M -8M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+112.73% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-214M 1.4B
Vorige openingsprijs	29.88
Vorige sluitingsprijs	28.53

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

27.895 / 30.16 Steun & Weerstand

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2026, 22:50 UTC

Winsten

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mei 2026, 22:49 UTC

Winsten

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mei 2026, 22:32 UTC

Winsten

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mei 2026, 22:57 UTC

Marktinformatie

Winsten

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mei 2026, 22:26 UTC

Winsten

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mei 2026, 22:24 UTC

Winsten

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mei 2026, 22:19 UTC

Winsten

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mei 2026, 22:13 UTC

Winsten

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mei 2026, 22:11 UTC

Winsten

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mei 2026, 22:11 UTC

Winsten

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mei 2026, 22:10 UTC

Winsten

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mei 2026, 22:08 UTC

Winsten

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mei 2026, 22:07 UTC

Winsten

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mei 2026, 22:05 UTC

Winsten

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

112.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.33 USD 112.73%

Hoogste 100 USD

Laagste 33 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Immunocore Holdings PLC ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

27.895 / 30.16Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.